Oncopeptides AB (publ) is a biotechnology company focused on developing pharmaceutical therapies to combat cancer. The firm's therapeutic innovations are intended for markets across the United States, Europe, and internationally. Its flagship product candidate, melflufen, is an advanced anti-cancer peptide drug conjugate specifically designed to treat adult patients afflicted with relapsed refractory multiple myeloma.